CERo Therapeutics Activates Additional Site for CERTAIN-T Trial
CERo Therapeutics says an additional clinical trial site has been activated for its ongoing Phase 1 CERTAIN-T trial of CER-1236 in hematological cancers.
Story updates
01:07:00 PM UTC
SquawkNews
UC Davis is the primary manufacturing site for CER-1236, site activation is expected to expand patient recruitment capacity and streamline treatment logisticsUpdate follows SRX’s previously announced definitive agreement to acquire CERo TherapeuticsNORTH PALM BEACH, Fla., Oct. 26, 2026 (GLOBE NEWSW…
01:07:30 PM UTC
SquawkNews
SRX Global said UC Davis, already the primary manufacturing site for CER-1236, is now activated as a clinical site for the Phase 1 CERTAIN-T trial, expected to expand recruitment and streamline treatment logistics.Material DetailsContext by AI AnalystThis is an early-stage operational update that m…